Cargando…

Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis

Pulmonary fibrosis is becoming an increasingly common pathology worldwide. Unfortunately, this disorder is characterized by a bad prognosis: no treatment is known, and the survival rate is dramatically low. One of the most frequent reasons for pulmonary fibrosis is hypersensitivity pneumonitis (HP)....

Descripción completa

Detalles Bibliográficos
Autores principales: Lemieszek, Marta Kinga, Golec, Marcin, Zwoliński, Jacek, Dutkiewicz, Jacek, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659202/
https://www.ncbi.nlm.nih.gov/pubmed/36361827
http://dx.doi.org/10.3390/ijms232113039
_version_ 1784830143326322688
author Lemieszek, Marta Kinga
Golec, Marcin
Zwoliński, Jacek
Dutkiewicz, Jacek
Milanowski, Janusz
author_facet Lemieszek, Marta Kinga
Golec, Marcin
Zwoliński, Jacek
Dutkiewicz, Jacek
Milanowski, Janusz
author_sort Lemieszek, Marta Kinga
collection PubMed
description Pulmonary fibrosis is becoming an increasingly common pathology worldwide. Unfortunately, this disorder is characterized by a bad prognosis: no treatment is known, and the survival rate is dramatically low. One of the most frequent reasons for pulmonary fibrosis is hypersensitivity pneumonitis (HP). As the main mechanism of pulmonary fibrosis is a pathology of the repair of wounded pulmonary epithelium with a pivotal role in epithelial–mesenchymal transition (EMT), we assumed that EMT silencing could prevent disease development. Because of several biological features including wound healing promotion, an ideal candidate for use in the treatment of pulmonary fibrosis seems to be cathelicidin. The aim of the studies was to understand the influence of cathelicidin on the EMT process occurring during lung fibrosis development in the course of HP. Cathelicidin’s impact on EMT was examined in a murine model of HP, wherein lung fibrosis was induced by chronic exposure to extract of Pantoea agglomerans (SE-PA) by real-time PCR and Western blotting. Studies revealed that mouse exposure to cathelicidin did not cause any side changes in the expression of investigated genes/proteins. Simultaneously, cathelicidin administered together or after SE-PA decreased the elevated level of myofibroblast markers (Acta2/α-smooth muscle actin, Cdh2/N-cadherin, Fn1/Fibronectin, Vim/vimentin) and increased the lowered level of epithelial markers (Cdh1/E-cadherin, Ocln/occludin). Cathelicidin provided with SE-PA or after cessation of SE-PA inhalations reduced the expression of EMT-associated factors (Ctnnd1/β-catenin, Nfkb1/NFκB, Snail1/Snail, Tgfb1/TGFβ1 Zeb1/ZEB1, Zeb2/ZEB2) elevated by P. agglomerans. Cathelicidin’s beneficial impact on the expression of genes/proteins involved in EMT was observed during and after the HP development; however, cathelicidin was not able to completely neutralize the negative changes. Nevertheless, significant EMT silencing in response to cathelicidin suggested the possibility of its use in the prevention/treatment of pulmonary fibrosis.
format Online
Article
Text
id pubmed-9659202
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96592022022-11-15 Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis Lemieszek, Marta Kinga Golec, Marcin Zwoliński, Jacek Dutkiewicz, Jacek Milanowski, Janusz Int J Mol Sci Article Pulmonary fibrosis is becoming an increasingly common pathology worldwide. Unfortunately, this disorder is characterized by a bad prognosis: no treatment is known, and the survival rate is dramatically low. One of the most frequent reasons for pulmonary fibrosis is hypersensitivity pneumonitis (HP). As the main mechanism of pulmonary fibrosis is a pathology of the repair of wounded pulmonary epithelium with a pivotal role in epithelial–mesenchymal transition (EMT), we assumed that EMT silencing could prevent disease development. Because of several biological features including wound healing promotion, an ideal candidate for use in the treatment of pulmonary fibrosis seems to be cathelicidin. The aim of the studies was to understand the influence of cathelicidin on the EMT process occurring during lung fibrosis development in the course of HP. Cathelicidin’s impact on EMT was examined in a murine model of HP, wherein lung fibrosis was induced by chronic exposure to extract of Pantoea agglomerans (SE-PA) by real-time PCR and Western blotting. Studies revealed that mouse exposure to cathelicidin did not cause any side changes in the expression of investigated genes/proteins. Simultaneously, cathelicidin administered together or after SE-PA decreased the elevated level of myofibroblast markers (Acta2/α-smooth muscle actin, Cdh2/N-cadherin, Fn1/Fibronectin, Vim/vimentin) and increased the lowered level of epithelial markers (Cdh1/E-cadherin, Ocln/occludin). Cathelicidin provided with SE-PA or after cessation of SE-PA inhalations reduced the expression of EMT-associated factors (Ctnnd1/β-catenin, Nfkb1/NFκB, Snail1/Snail, Tgfb1/TGFβ1 Zeb1/ZEB1, Zeb2/ZEB2) elevated by P. agglomerans. Cathelicidin’s beneficial impact on the expression of genes/proteins involved in EMT was observed during and after the HP development; however, cathelicidin was not able to completely neutralize the negative changes. Nevertheless, significant EMT silencing in response to cathelicidin suggested the possibility of its use in the prevention/treatment of pulmonary fibrosis. MDPI 2022-10-27 /pmc/articles/PMC9659202/ /pubmed/36361827 http://dx.doi.org/10.3390/ijms232113039 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lemieszek, Marta Kinga
Golec, Marcin
Zwoliński, Jacek
Dutkiewicz, Jacek
Milanowski, Janusz
Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title_full Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title_fullStr Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title_full_unstemmed Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title_short Cathelicidin Treatment Silences Epithelial–Mesenchymal Transition Involved in Pulmonary Fibrosis in a Murine Model of Hypersensitivity Pneumonitis
title_sort cathelicidin treatment silences epithelial–mesenchymal transition involved in pulmonary fibrosis in a murine model of hypersensitivity pneumonitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659202/
https://www.ncbi.nlm.nih.gov/pubmed/36361827
http://dx.doi.org/10.3390/ijms232113039
work_keys_str_mv AT lemieszekmartakinga cathelicidintreatmentsilencesepithelialmesenchymaltransitioninvolvedinpulmonaryfibrosisinamurinemodelofhypersensitivitypneumonitis
AT golecmarcin cathelicidintreatmentsilencesepithelialmesenchymaltransitioninvolvedinpulmonaryfibrosisinamurinemodelofhypersensitivitypneumonitis
AT zwolinskijacek cathelicidintreatmentsilencesepithelialmesenchymaltransitioninvolvedinpulmonaryfibrosisinamurinemodelofhypersensitivitypneumonitis
AT dutkiewiczjacek cathelicidintreatmentsilencesepithelialmesenchymaltransitioninvolvedinpulmonaryfibrosisinamurinemodelofhypersensitivitypneumonitis
AT milanowskijanusz cathelicidintreatmentsilencesepithelialmesenchymaltransitioninvolvedinpulmonaryfibrosisinamurinemodelofhypersensitivitypneumonitis